Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
  1. 3 Insider Initial Statement of Ownership
  2. 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $8.10 ($115,726)
  3. 4 Open-market sale President and CEO sold 1,010 shares at $9.01 ($9,099)
  4. 4 Open-market sale President and CEO sold 32,336 shares at an average $9.12 ($295,065)
  5. 4 Open-market sale President and CEO sold 26,056 shares at an average $9.15 ($238,291)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale President and CEO sold 64,967 shares at an average $9.16 ($595,045)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale President and CEO sold 85,536 shares at an average $9.28 ($793,907)
  15. 4 Exercise or conversion Chief Technology Officer & EVP acquired 5,000 shares (option exercise)
  16. 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $8.57 ($122,325)
  17. 4 Open-market sale President and CEO sold 233 shares at $9.00 ($2,097)
  18. 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $7.58 ($108,266)
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale Aunins John G. sold 1,738 shares at $11.02 ($19,153)

Page 14 of 19 · 380 filings